Dyax Corp (DYAX) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Dyax Corp. Announces Third Quarter 2015 Financial Results
October 28, 2015 4:01 PM EDTBURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2015. Dyax will host a webcast to review these results in conjunction with the Companys Research and Development Day on Monday, November 2, 2015 at 8:00 a.m. (ET).
Recent highlights include:
Protocol finalized with the U.S. Food and Drug Administration for Dyaxs single, pivotal Phase 3 clinical trial evaluating DX-2930 in hereditary angioedema (HAE); Receipt of orphan medicinal product designation in the European Union for DX-2930 for the treatment of HAE;... More